{"id":27826,"date":"2022-07-19T22:56:00","date_gmt":"2022-07-19T14:56:00","guid":{"rendered":"https:\/\/flcube.com\/?p=27826"},"modified":"2025-02-24T22:58:11","modified_gmt":"2025-02-24T14:58:11","slug":"hengrui-medicine-launches-revelutamide-for-metastatic-prostate-cancer-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=27826","title":{"rendered":"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China"},"content":{"rendered":"\n<p>Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China&#8217;s homegrown innovative androgen receptor (AR) inhibitor, for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. The drug received conditional market approval from the National Medical Products Administration (NMPA) in June 2022 and was first prescribed at Fudan University Affiliated Cancer Hospital in Shanghai.<\/p>\n\n\n\n<p><strong>Nationwide Availability<\/strong><br>On the same day, experts in Beijing, Shanghai, Guangzhou, Nanjing, Wuhan, Jinan, Changsha, Guiyang, and other cities issued the first local prescriptions. Patients can access revelutamide through direct-to-patient pharmacies nationwide with a valid prescription.<\/p>\n\n\n\n<p><strong>Drug Profile<\/strong><br>Revelutamide is a second-generation AR inhibitor with stronger inhibitory effects and no agonistic activity compared to first-generation AR inhibitors. Supported by the National \u201cThirteenth Five-Year Plan\u201d Major New Drug Creation Project in 2018, the drug addresses the growing need for advanced prostate cancer treatments in China.<\/p>\n\n\n\n<p><strong>Prostate Cancer Context<\/strong><br>Prostate cancer incidence in China has risen significantly, with new cases increasing from ~60,000 in 2015 to ~115,000 in 2020, according to the World Health Organization. Revelutamide&#8217;s launch underscores efforts to combat this trend.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China&#8217;s homegrown innovative androgen receptor (AR)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,2586,40],"class_list":["post-27826","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-hengrui-pharmaceuticals","tag-market-launch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China&#039;s homegrown innovative androgen receptor (AR) inhibitor, for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. The drug received conditional market approval from the National Medical Products Administration (NMPA) in June 2022 and was first prescribed at Fudan University Affiliated Cancer Hospital in Shanghai.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=27826\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=27826\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-19T14:56:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-24T14:58:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27826#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27826\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China\",\"datePublished\":\"2022-07-19T14:56:00+00:00\",\"dateModified\":\"2025-02-24T14:58:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27826\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Hengrui Pharmaceuticals\",\"Market launch\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27826#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27826\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=27826\",\"name\":\"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-07-19T14:56:00+00:00\",\"dateModified\":\"2025-02-24T14:58:11+00:00\",\"description\":\"Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China's homegrown innovative androgen receptor (AR) inhibitor, for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. The drug received conditional market approval from the National Medical Products Administration (NMPA) in June 2022 and was first prescribed at Fudan University Affiliated Cancer Hospital in Shanghai.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27826#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27826\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27826#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China - Insight, China&#039;s Pharmaceutical Industry","description":"Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China's homegrown innovative androgen receptor (AR) inhibitor, for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. The drug received conditional market approval from the National Medical Products Administration (NMPA) in June 2022 and was first prescribed at Fudan University Affiliated Cancer Hospital in Shanghai.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=27826","og_locale":"en_US","og_type":"article","og_title":"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=27826","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-07-19T14:56:00+00:00","article_modified_time":"2025-02-24T14:58:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=27826#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=27826"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China","datePublished":"2022-07-19T14:56:00+00:00","dateModified":"2025-02-24T14:58:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=27826"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Hengrui Pharmaceuticals","Market launch"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=27826#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=27826","url":"https:\/\/flcube.com\/?p=27826","name":"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-07-19T14:56:00+00:00","dateModified":"2025-02-24T14:58:11+00:00","description":"Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China's homegrown innovative androgen receptor (AR) inhibitor, for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. The drug received conditional market approval from the National Medical Products Administration (NMPA) in June 2022 and was first prescribed at Fudan University Affiliated Cancer Hospital in Shanghai.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=27826#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=27826"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=27826#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27826"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27826\/revisions"}],"predecessor-version":[{"id":27827,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27826\/revisions\/27827"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}